CURRENT MEDICATIONS OVERVIEW,,
MEDICATION,GENE(S),PRESCRIBING CONSIDERATIONS BASED ON myDNA TEST
"Duloxetine","CYP1A2CYP2D6",Usual prescribing considerations apply
"Ibuprofen",CYP2C9,Usual prescribing considerations apply
MEDICATIONS THAT DO NOT HAVE PRESCRIBING CONSIDERATIONS BASED ON myDNA TEST,,
"ethinylestradiol / levonorgestrel (Levonorgestrel And Ethinyl Estradiol Tablets, 0.1 Mg/0.02 Mg)",,
MEDICATIONS WITH MAJOR PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"Antidepressants -SSRIs",Citalopram,CYP2C19,Adverse effects,"CPIC2, TGA3"
"",Escitalopram,CYP2C19,Adverse effects,"CPIC2, TGA4"
"",Sertraline,CYP2C19,Adverse effects,CPIC2
"Antidepressants -tricyclicantidepressants",Amitriptyline,"CYP2D6CYP2C19",Adverse effects,CPIC5
Clomipramine,"CYP2D6CYP2C19",Adverse effects,CPIC5,
Doxepin,"CYP2D6CYP2C19",Adverse effects,CPIC5,
Imipramine,"CYP2D6CYP2C19",Adverse effects,CPIC5,
MEDICATIONS WITH MAJOR PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
Antifungals - Azoles,Voriconazole,CYP2C19,"Increased therapeutic and/oradverse effects",CPIC6
Antiplatelet drugs,Clopidogrel,CYP2C19,Reduced / inadequate response,CPIC7
Benzodiazepines,Clobazam,CYP2C19,Adverse effects,FDA8
"",Diazepam,CYP2C19,Adverse effects,-
Statins,Simvastatin,"SLCO1B1CYP3A4",Adverse effects,CPIC9
MEDICATIONS WITH MINOR PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"ADHD -miscellaneous agents",Atomoxetine,CYP2D6,Adverse effects,-
Antiarrhythmics,Flecainide,CYP2D6,Adverse effects,DPWG10
"",Propafenone,CYP2D6,Adverse effects,DPWG10
Anticoagulants,Acenocoumarol,"VKORC1CYP2C9","Increased acenocoumarolsensitivity",
"",Warfarin,"VKORC1CYP2C9",Increased warfarin sensitivity,FDA11
"Antidepressants -other",Moclobemide,CYP2C19,Adverse effects,-
"Antidepressants -serotoninnoradrenalinereuptake inhibitors",Venlafaxine,CYP2D6,Adverse effects,DPWG10
"Antidepressants -SSRIs",Paroxetine,CYP2D6,Adverse effects,CPIC2
"Antidepressants -tricyclicantidepressants",Desipramine,CYP2D6,Adverse effects,CPIC5
"",Nortriptyline,CYP2D6,Adverse effects,CPIC5
Antidiabetics,Gliclazide,"CYP2C9CYP2C19","Increased therapeutic and/oradverse effects",-
Antiemetics,Ondansetron,CYP2D6,"Increased therapeutic and/oradverse effects",CPIC12
Antihistamines,Chlorpheniramine,CYP2D6,Adverse effects,-
"",Dexchlorpheniramine,CYP2D6,Adverse effects,-
Antipsychotics,Aripiprazole,CYP2D6,Adverse effects,-
"",Brexpiprazole,CYP2D6,Adverse effects,-
"",Haloperidol,CYP2D6,Adverse effects,-
"",Pimozide,CYP2D6,Adverse effects,
"",Risperidone,CYP2D6,Adverse effects,DPWG10
"",Zuclopenthixol,CYP2D6,Adverse effects,DPWG10
Antitussives,Dextromethorphan,CYP2D6,Altered response,-
Beta blockers,Metoprolol,CYP2D6,Adverse effects,DPWG10
"Immunomodulatorsand antineoplastics",Tamoxifen,CYP2D6,Reduced / inadequate response,CPIC13
Miscellaneous,Cyclophosphamide,CYP2C19,Reduced / inadequate response,-
"",Eliglustat,CYP2D6,Adverse effects,TGA14
"",Naltrexone,OPRM1,"Associated with reducedresponse to naltrexone",
"",Proguanil,CYP2C19,Reduced / inadequate response,-
Neurological drugs,Tetrabenazine,CYP2D6,Adverse effects,FDA15
MEDICATIONS WITH MINOR PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
Opioid Analgesics,Morphine,OPRM1,"Associated with increasedtherapeutic and/or adverseeffects to morphine",-
"Proton pumpinhibitors",Dexlansoprazole,CYP2C19,"Increased therapeutic and/oradverse effects",FDA16
"",Esomeprazole,CYP2C19,"Increased therapeutic and/oradverse effects",-
"",Lansoprazole,CYP2C19,"Increased therapeutic and/oradverse effects",-
"",Omeprazole,CYP2C19,"Increased therapeutic and/oradverse effects",-
"",Pantoprazole,CYP2C19,"Increased therapeutic and/oradverse effects",-
"",Rabeprazole,CYP2C19,"Increased therapeutic and/oradverse effects",-
Statins,Atorvastatin,"SLCO1B1CYP3A4",Adverse effects,-
MEDICATIONS WITH USUAL PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"Angiotensin receptorblockers",Irbesartan,CYP2C9,"No altered effect predicted bygenotype",-
"",Losartan,CYP2C9,"No altered effect predicted bygenotype",-
"Anticholinergics(genitourinary)",Darifenacin,CYP2D6,"No altered effect predicted bygenotype",-
"",Fesoterodine,CYP2D6,"No altered effect predicted bygenotype",-
"",Tolterodine,CYP2D6,"No altered effect predicted bygenotype",-
Anticholinesterases,Donepezil,CYP2D6,"No altered effect predicted bygenotype",-
"",Galantamine,CYP2D6,"No altered effect predicted bygenotype",-
"Antidepressants -other",Mirtazapine,"CYP2D6CYP1A2","No altered effect predicted bygenotype",-
"",Vortioxetine,CYP2D6,"No altered effect predicted bygenotype",-
"Antidepressants -serotoninnoradrenalinereuptake inhibitors",Duloxetine,"CYP2D6CYP1A2","No altered effect predicted bygenotype",-
"Antidepressants -SSRIs",Fluoxetine,"CYP2D6CYP2C9","No altered effect predicted bygenotype",-
"",Fluvoxamine,"CYP2D6CYP1A2","No altered effect predicted bygenotype",CPIC2
Antidiabetics,Glimepiride,CYP2C9,"No altered effect predicted bygenotype",-
"",Glyburide,CYP2C9,"No altered effect predicted bygenotype",-
Antiemetics,Metoclopramide,CYP2D6,"No altered effect predicted bygenotype",-
MEDICATIONS WITH USUAL PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
Antiepileptics,Phenytoin,CYP2C9,"No altered effect predicted bygenotype",CPIC17
Antihistamines,Promethazine,CYP2D6,Adverse effects,-
Antipsychotics,Chlorpromazine,CYP2D6,"No altered effect predicted bygenotype",-
"",Clozapine,CYP1A2,"No altered effect predicted bygenotype",-
"",Olanzapine,CYP1A2,"No altered effect predicted bygenotype",-
"",Quetiapine,CYP3A4,"No altered effect predicted bygenotype",-
Beta blockers,Carvedilol,CYP2D6,"No altered effect predicted bygenotype",-
"",Nebivolol,CYP2D6,"No altered effect predicted bygenotype",-
"",Propranolol,"CYP2D6CYP1A2","No altered effect predicted bygenotype",-
Calcineurin inhibitors,Tacrolimus,CYP3A5,"No altered effect predicted bygenotype",CPIC18
"Glaucoma - ocularpreparations",Timolol,CYP2D6,"No altered effect predicted bygenotype",-
Hypnotics,Melatonin,CYP1A2,"No altered effect predicted bygenotype",-
Miscellaneous,Atazanavir,CYP3A5,"No altered effect predicted bygenotype",-
NSAIDs,Celecoxib,CYP2C9,"No altered effect predicted bygenotype",-
"",Diclofenac,CYP2C9,"No altered effect predicted bygenotype",-
"",Flurbiprofen,CYP2C9,"No altered effect predicted bygenotype",-
"",Ibuprofen,CYP2C9,"No altered effect predicted bygenotype",-
"",Indomethacin,CYP2C9,"No altered effect predicted bygenotype",-
"",Mefenamic Acid,CYP2C9,"No altered effect predicted bygenotype",-
"",Meloxicam,CYP2C9,"No altered effect predicted bygenotype",-
"",Piroxicam,CYP2C9,"No altered effect predicted bygenotype",-
Opioid Analgesics,Codeine,"CYP2D6OPRM1","Associated with increasedsensitivity to codeine",CPIC19
"",Hydrocodone,CYP2D6,"No altered effect predicted bygenotype",
"",Oxycodone,CYP2D6,"No altered effect predicted bygenotype",DPWG10
"",Tramadol,CYP2D6,"No altered effect predicted bygenotype",DPWG10
Psychostimulants,Dextroamphetamine,CYP2D6,"No altered effect predicted bygenotype",-
"",Lisdexamfetamine,CYP2D6,"No altered effect predicted bygenotype",-
Statins,Fluvastatin,"SLCO1B1CYP2C9","No altered effect predicted bygenotype",-
MEDICATIONS WITH USUAL PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"",Pravastatin,SLCO1B1,"No altered effect predicted bygenotype",-
Rosuvastatin,SLCO1B1,"No altered effect predicted bygenotype",-,
